ZA201705662B - Anti-transthyretin antibodies - Google Patents
Anti-transthyretin antibodiesInfo
- Publication number
- ZA201705662B ZA201705662B ZA2017/05662A ZA201705662A ZA201705662B ZA 201705662 B ZA201705662 B ZA 201705662B ZA 2017/05662 A ZA2017/05662 A ZA 2017/05662A ZA 201705662 A ZA201705662 A ZA 201705662A ZA 201705662 B ZA201705662 B ZA 201705662B
- Authority
- ZA
- South Africa
- Prior art keywords
- transthyretin antibodies
- transthyretin
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109001P | 2015-01-28 | 2015-01-28 | |
| US201562266557P | 2015-12-11 | 2015-12-11 | |
| PCT/IB2016/050414 WO2016120809A1 (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201705662B true ZA201705662B (en) | 2018-08-29 |
Family
ID=55361912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/05662A ZA201705662B (en) | 2015-01-28 | 2017-08-21 | Anti-transthyretin antibodies |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20160257736A1 (enExample) |
| EP (1) | EP3250594B1 (enExample) |
| JP (2) | JP6875280B2 (enExample) |
| KR (1) | KR102619359B1 (enExample) |
| CN (1) | CN107428822B (enExample) |
| AU (1) | AU2016210887B2 (enExample) |
| CA (1) | CA2974911A1 (enExample) |
| CO (1) | CO2017008469A2 (enExample) |
| CU (1) | CU24532B1 (enExample) |
| EA (1) | EA036048B1 (enExample) |
| ES (1) | ES2905311T3 (enExample) |
| MX (1) | MX391789B (enExample) |
| MY (1) | MY193674A (enExample) |
| PE (1) | PE20180200A1 (enExample) |
| SA (1) | SA517381991B1 (enExample) |
| SG (1) | SG11201706125QA (enExample) |
| TW (2) | TWI718121B (enExample) |
| WO (1) | WO2016120809A1 (enExample) |
| ZA (1) | ZA201705662B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI718121B (zh) * | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| EP3478714A2 (en) * | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7017013B2 (ja) * | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| JP7016470B2 (ja) * | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| SG11202002489YA (en) | 2017-10-06 | 2020-04-29 | Prothena Biosciences Ltd | Anti-transthyretin antibodies |
| KR102581734B1 (ko) * | 2017-10-06 | 2023-09-22 | 네오토프 뉴로사이언스 리미티드 | 트랜스타이레틴의 검출 방법 |
| MA51223A (fr) | 2017-11-29 | 2020-10-07 | Prothena Biosciences Ltd | Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine |
| WO2020247452A1 (en) * | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| CN112816453B (zh) * | 2021-02-09 | 2022-07-08 | 黑龙江大学 | 蛋白在预测药物性能上的应用 |
| CN117603921A (zh) * | 2023-11-27 | 2024-02-27 | 四川大学华西医院 | 一种重组腺相关病毒及轻链型淀粉样变动物模型的构建方法 |
| CN122374011A (zh) | 2023-12-15 | 2026-07-10 | 诺和诺德股份有限公司 | 稳定的液体制剂 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| MY128897A (en) | 1999-02-05 | 2007-02-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| EP1470146B8 (en) | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| DE50308030D1 (de) | 2002-11-29 | 2007-10-04 | Boehringer Ingelheim Pharma | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| EP1820022B1 (en) | 2004-11-10 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| WO2007124345A2 (en) | 2006-04-21 | 2007-11-01 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Beta-amyloid pet imaging agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| EP2522730A1 (en) | 2007-03-02 | 2012-11-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| WO2010030203A1 (en) * | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| JP2016514091A (ja) * | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス， インコーポレイテッド | トランスサイレチン抗体およびその使用 |
| TWI718121B (zh) * | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
-
2016
- 2016-01-27 TW TW105102534A patent/TWI718121B/zh not_active IP Right Cessation
- 2016-01-27 TW TW110100084A patent/TWI781507B/zh not_active IP Right Cessation
- 2016-01-28 ES ES16704940T patent/ES2905311T3/es active Active
- 2016-01-28 KR KR1020177023748A patent/KR102619359B1/ko active Active
- 2016-01-28 WO PCT/IB2016/050414 patent/WO2016120809A1/en not_active Ceased
- 2016-01-28 SG SG11201706125QA patent/SG11201706125QA/en unknown
- 2016-01-28 MX MX2017009804A patent/MX391789B/es unknown
- 2016-01-28 CA CA2974911A patent/CA2974911A1/en active Pending
- 2016-01-28 EA EA201791711A patent/EA036048B1/ru unknown
- 2016-01-28 PE PE2017001286A patent/PE20180200A1/es unknown
- 2016-01-28 MY MYPI2017702749A patent/MY193674A/en unknown
- 2016-01-28 US US15/009,666 patent/US20160257736A1/en not_active Abandoned
- 2016-01-28 CU CU2017000096A patent/CU24532B1/es unknown
- 2016-01-28 CN CN201680015800.8A patent/CN107428822B/zh active Active
- 2016-01-28 AU AU2016210887A patent/AU2016210887B2/en not_active Ceased
- 2016-01-28 JP JP2017540249A patent/JP6875280B2/ja active Active
- 2016-01-28 EP EP16704940.2A patent/EP3250594B1/en active Active
-
2017
- 2017-07-26 SA SA517381991A patent/SA517381991B1/ar unknown
- 2017-08-21 ZA ZA2017/05662A patent/ZA201705662B/en unknown
- 2017-08-22 CO CONC2017/0008469A patent/CO2017008469A2/es unknown
-
2021
- 2021-04-22 JP JP2021072547A patent/JP7219928B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3250594A1 (en) | 2017-12-06 |
| KR102619359B1 (ko) | 2024-01-02 |
| MX391789B (es) | 2025-03-21 |
| WO2016120809A1 (en) | 2016-08-04 |
| CN107428822B (zh) | 2021-11-23 |
| MY193674A (en) | 2022-10-24 |
| JP2018509889A (ja) | 2018-04-12 |
| AU2016210887A1 (en) | 2017-08-10 |
| CN107428822A (zh) | 2017-12-01 |
| CU24532B1 (es) | 2021-07-02 |
| TWI781507B (zh) | 2022-10-21 |
| CA2974911A1 (en) | 2016-08-04 |
| TW201636372A (zh) | 2016-10-16 |
| JP7219928B2 (ja) | 2023-02-09 |
| KR20170120607A (ko) | 2017-10-31 |
| TWI718121B (zh) | 2021-02-11 |
| ES2905311T3 (es) | 2022-04-07 |
| EA036048B1 (ru) | 2020-09-18 |
| AU2016210887B2 (en) | 2021-11-04 |
| EP3250594B1 (en) | 2021-11-17 |
| CU20170096A7 (es) | 2018-03-13 |
| PE20180200A1 (es) | 2018-01-31 |
| SG11201706125QA (en) | 2017-08-30 |
| BR112017016324A2 (pt) | 2018-03-27 |
| JP2021129562A (ja) | 2021-09-09 |
| US20160257736A1 (en) | 2016-09-08 |
| MX2017009804A (es) | 2018-08-15 |
| EA201791711A1 (ru) | 2017-11-30 |
| SA517381991B1 (ar) | 2021-12-13 |
| TW202118782A (zh) | 2021-05-16 |
| JP6875280B2 (ja) | 2021-05-26 |
| CO2017008469A2 (es) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259048A (en) | Antibodies against ror-1 | |
| ZA201708128B (en) | Tau-binding antibodies | |
| ZA201800027B (en) | Tau-binding antibodies | |
| SG10201913864RA (en) | Anti-LAG-3 Antibodies | |
| ZA201705663B (en) | Anti-transthyretin antibodies | |
| LT3354729T (lt) | Anti-garp antikūnas | |
| GB201521393D0 (en) | Antibodies | |
| GB201521391D0 (en) | Antibodies | |
| SG11201706126WA (en) | Anti-transthyretin antibodies | |
| GB201521382D0 (en) | Antibodies | |
| IL255323A0 (en) | Anti-fcrn antibodies | |
| SG11201706125QA (en) | Anti-transthyretin antibodies | |
| IL268889A (en) | Anti-EPHA4 antibody | |
| GB201515351D0 (en) | Antibody | |
| GB201600871D0 (en) | Antibody | |
| LT3336185T (lt) | Antikūnas | |
| GB201509907D0 (en) | Antibodies | |
| GB201503438D0 (en) | Antibodies | |
| GB201522394D0 (en) | Antibodies | |
| IL284022A (en) | Anti-transthyretin antibodies | |
| GB201518728D0 (en) | Antibodies | |
| GB201515570D0 (en) | Anti-LAG-3 antibodies | |
| GB201515572D0 (en) | Anti-LAG-3 antibodies | |
| GB201514425D0 (en) | Antibodies | |
| GB201508437D0 (en) | Antibodies |